全身免疫炎症指数对HER2阴性晚期胃癌患者一线化疗疗效及生存结局的预测价值  

Value of systemic immune inflammation index in predicting the efficacy of first-line chemotherapy and survival outcome in patients with HER2 negative advanced gastric cancer

作　　者：周阳阳[1] 刘静[1] 朱叶青 杨燕[1] 周争光[1] 王明喜[1] ZHOU Yangyang;LIU Jing;ZHU Yeqing;YANG Yan;ZHOU Zhengguang;WANG Mingxi(Department of Medical Oncology,the First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui 233004,China;不详)

机构地区：[1]蚌埠医学院第一附属医院肿瘤内科,安徽蚌埠233004 [2]蚌埠医学院临床医学院,安徽蚌埠233030

出　　处：《中华全科医学》2023年第12期2031-2035,共5页Chinese Journal of General Practice

基　　金：安徽省卫健委卫生健康科研重点项目(AHWJ2022a010);安徽省大学生创新训练计划项目(S202110367134);蚌埠医学院自然科学基金重点项目(2021byzd110)。

摘　　要：目的探讨全身免疫炎症指数(SII)与晚期胃癌患者一线化疗疗效及预后的相关性。方法回顾性收集2017年2月—2021年6月于蚌埠医学院第一附属医院肿瘤内科接受一线化疗的90例HER2阴性晚期胃癌患者的病理资料,根据基线血常规化验结果计算SII值。分别采用受试者工作特征曲线和X-tile软件选取SII治疗疗效和预后的最佳临界值,根据临界值将晚期胃癌患者分为高、低SII组,分析HER2阴性晚期胃癌患者基线SII与其临床病理特征、一线化疗疗效、无进展生存期(PFS)和总生存期(OS)的关系。结果共纳入90例HER2阴性晚期胃癌患者,高、低SII组患者的客观缓解率分别为3.45%(1/29)和19.67%(12/61),疾病控制率分别为41.38%(12/29)和77.05%(47/61)。基线SII越低,患者化疗疗效越好(χ^(2)=11.075,P=0.001)。低SII组患者的PFS显著长于高SII组(4.57个月vs.2.13个月,P<0.001),低SII组患者的OS亦显著长于高SII组(9.83个月vs.3.97个月,P<0.001)。单因素和多因素Cox分析结果显示,基线SII水平是HER2阴性晚期胃癌患者一线治疗PFS和OS的独立影响因素。结论基线SII水平有预测HER2阴性晚期胃癌患者一线化疗疗效和生存结局的潜在价值,高SII与疗效差和不良预后有关。Objective To explore the value of the systemic immune-inflammatory index(SII)in predicting the efficacy of first-line chemotherapy and survival in patients with human epidermal growth factor receptor 2(HER2)negative advanced gastric cancer.Methods The clinical data of advanced gastric cancer patients who received standard first-line chemotherapy at the Department of Medical Oncology,the First Affiliated Hospital of Bengbu Medical College from February 2017 to June 2021 were retrospectively collected.The SII values were calculated based on the results of the baseline routine blood test.The receiver operating characteristic(ROC)curve and X-tile software were used to determine the optimal cut off value of SII for therapeutic effect and prognosis,and patients was classified into high and low SII groups.The relationship between SII and clinicopathological characteristics,efficacy of first-line chemotherapy,progression-free survival(PFS)and overall survival(OS)of patients with advanced gastric cancer was analyzed.Results A total of 90 patients with advanced gastric cancer were enrolled.The objective response rates of patients in the high and low SII groups were 3.45%(1/29)and 19.67%(12/61),and the disease control rates were 41.38%(12/29)and 77.05%(47/61),respectively;patients with lower baseline SII had better chemotherapy efficacy(χ^(2)=11.075,P=0.001).The mPFS of patients in the low SII group was significantly longer than that of patients in the high SII group(4.57 months vs.2.13 months,P<0.001),and patients with low SII achieved a longer OS than patients with high SII(9.83 months vs.3.97 months,P<0.001).The results of univariate and multivariate Cox analysis showed that the level of baseline SII was an independent prognostic factor affecting PFS and OS of first-line therapy in patients with advanced gastric cancer.Conclusion The baseline level of SII has potential value in predicting the efficacy and prognosis of first-line chemotherapy in patients with advanced gastric cancer,and patients with high SII tend to hav

关 键 词：晚期胃癌 全身免疫炎症指数 疗效 预后 

分 类 号：R735.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]